Rheumatology Network

Complete Coverage at ACR2014

Must you regretfully miss the event of the year, the American College of Rheumatology annual meeting? Or are you planning to dive into the maelstrom of events at ACR2014? Either way, Rheumatology Network will be there to alert you to the latest and best from the conference. New this year: On-the-spot commentary from Washington DC rheumatologist Paul DeMarco MD.

Recent Content

(ACR2014) A test for 14-3-3-eta, a joint-derived protein that contributes to erosion, proves a powerful aid to diagnosis of rheumatoid arthritis and ankylosing spondylitis, and may also predict response to treatment.

(ACR2014) With FDA approval of the new IL-17A inhibitor expected soon, results of the latest clinical trials presented here show the expected benefits of a first-of-its-kind treatment for axial spondylitis, psoriatic arthritis, and psoriasis.

(ACR2014) To this rheumatologist in attendance, the early announcement of changes to rheumatoid arthritis guidelines -- and some of the changes themselves -- were the big surprise of the American College of Rheumatology annual meeting.

Early comparisons of patients with rheumatic disease who use marijuana with those who don't show that the practice is not associated with better pain relief. But it is associated with some "sobering" consequences.

(ACR 2014) The American College of Rheumatology’s 2015 draft recommendations for managing rheumatoid arthritis include not only new agents but also tried-and-true therapies within the context of treat-to-target.

(ACR2014) These researchers learned what is actually happening to many gout patients who flare, and offer powerful reasons for its doctors to do better.

Treating gout with allopurinol is certainly less costly than no treatment whatever, all things considered. But a study shows even a more expensive combination may be cost-effective too.

By clicking Accept, you agree to become a member of the UBM Medica Community.